Mirion Technologies Q4 Earnings Announcement Scheduled
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy MIR?
Source: seekingalpha
- Earnings Announcement Date: Mirion Technologies is set to announce its Q4 earnings on February 10th after market close, with significant attention from investors regarding its performance impact on stock price.
- Earnings Expectations: The consensus EPS estimate stands at $0.16, reflecting a year-over-year decline of 5.9%, indicating potential profitability challenges that may affect investor confidence.
- Revenue Expectations: Revenue is projected at $281.17 million, representing a 10.6% year-over-year increase, highlighting the company's growth potential despite the decline in profitability.
- Historical Performance Review: Over the past two years, Mirion has exceeded EPS estimates 75% of the time and revenue estimates 88% of the time, demonstrating its capability in managing market expectations effectively.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MIR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MIR
Wall Street analysts forecast MIR stock price to rise
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 21.480
Low
29.00
Averages
30.60
High
34.00
Current: 21.480
Low
29.00
Averages
30.60
High
34.00
About MIR
Mirion Technologies, Inc. is a global provider of radiation detection, measurement, analysis, and monitoring solutions to the nuclear, medical, defense, and research end markets. The Company's segments include Medical, and Nuclear & Safety. The Medical segment includes products and services for radiation therapy, nuclear medicine and personal dosimetry. This segment’s principal product offering is in Radiation Therapy Quality Assurance, which includes solutions for calibrating and/or verifying imaging, treatment machine, patient treatment plan, and patient treatment accuracy. The Nuclear & Safety segment includes products and services focused on addressing critical radiation safety, measurement and analysis applications across nuclear energy, laboratories and research and other industrial markets such as defense. For nuclear power plants (NPPs), it sells products and services for use at any stage of their life (construction, operation, decommissioning and dismantling).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Mirion Executives to Present at Citi's Global Industrial Tech Conference
- Executive Presentation: Mirion's Chairman and CEO Thomas Logan, along with CFO Brian Schopfer, will present at Citi's Global Industrial Tech and Mobility Conference on February 18, 2026, at 2:40 PM ET, highlighting the company's leadership in radiation safety.
- Live Webcast Details: The presentation will be webcast live on Mirion's Investor Relations Page, where a link will be available under the 'Events and Presentations' section, ensuring investors can access real-time updates on the company's developments.
- Company Overview: Mirion is a global leader in radiation safety, science, and medicine, dedicated to delivering vital protection through innovative technologies that serve R&D labs, nuclear facilities, and healthcare, showcasing its broad application potential across diverse markets.
- Global Operations: Headquartered in Atlanta, GA, Mirion employs approximately 3,200 people and operates in 12 countries, demonstrating its significant influence and market penetration in the global radiation safety technology sector.
See More
Mirion Technologies Reports Record Orders and Strong 2026 Guidance
- Record Orders: Mirion Technologies achieved over $1 billion in orders for 2025, primarily driven by strong performance in the nuclear power market, with expectations for continued double-digit organic growth into 2026, highlighting the company's strategic advantage in the nuclear sector.
- Acquisition-Driven Growth: The acquisitions of Certrec and Paragon Energy Solutions have increased Mirion's nuclear power revenue to approximately 40% of total revenue, which not only strengthens the company's market position but also lays a solid foundation for future growth.
- 2026 Financial Outlook: The company expects total revenue growth of 22% to 24% for 2026, with adjusted EBITDA projected between $285 million and $300 million, indicating robust profitability and sustained market demand.
- Adjusted Free Cash Flow: Adjusted free cash flow for 2026 is expected to range from $155 million to $175 million, reflecting ongoing improvements in capital management and operational efficiency, further enhancing investor confidence.
See More
Mirion (MIR) Q4 2025 Earnings Call Transcript
See More
Mirion Appoints New Executives to Drive Growth Strategy
- Nuclear Strategy Leadership: Tighe Smith has been appointed as Chief Nuclear Officer to lead the global nuclear strategy, leveraging over 20 years of nuclear engineering experience to ensure Mirion remains competitive in the rapidly expanding advanced small modular reactor market, thereby driving long-term growth in the nuclear sector.
- Nuclear Medicine Market Expansion: Shelia Webb has been promoted to President of Nuclear Medicine, focusing on integrating the ec2Software and Capintec brands to advance cancer care, utilizing her successful experience in building digital ecosystems to enhance Mirion's position in this evolving market.
- AI Strategy Innovation: Shahmeer Mirza has been appointed as Chief Artificial Intelligence & Digital Officer, tasked with driving Mirion's digital transformation by implementing responsible AI strategies to optimize operational processes and create new revenue streams, thus improving overall operational efficiency.
- Enhanced Global Impact: Mirion's solutions are deployed in over 98% of the world's nuclear power plants and more than 6,000 cancer centers, and these executive appointments further strengthen the company's ability to deliver safe and reliable innovations in highly regulated environments, ensuring meaningful value for global users.
See More
Mirion Technologies Q4 Earnings Analysis
- Earnings Performance: Mirion Technologies reported a Q4 non-GAAP EPS of $0.15, missing expectations by $0.01, indicating pressure on profitability that could undermine investor confidence.
- Revenue Growth: The company achieved revenue of $277.4 million, reflecting a 9.1% year-over-year increase; however, it fell short of expectations by $3.77 million, suggesting that market demand has not fully translated into sales growth, which may impact future business expansion.
- Market Reaction Analysis: Given the disappointing earnings report, Mirion Technologies' stock price may face downward pressure, prompting investors to closely monitor the company's strategic adjustments and market performance to assess its long-term investment value.
- Future Outlook: Despite current challenges reflected in the earnings report, the company must leverage innovation and market expansion to enhance performance in a competitive landscape, ensuring sustainable growth moving forward.
See More
Mirion Reports 9.1% Revenue Growth in Q4
- Significant Revenue Growth: Mirion reported fourth-quarter revenues of $277.4 million for 2025, reflecting a 9.1% year-over-year increase, indicating strong demand in the nuclear and medical markets that further solidifies its market position.
- Net Income Improvement: The GAAP net income for Q4 was $17.8 million, an 11.9% increase from $15.9 million in the same quarter of 2024, showcasing the company's success in cost control and operational efficiency, which enhances investor confidence.
- Optimistic Guidance: Mirion anticipates a total revenue growth rate of 22% to 24% for 2026, with adjusted EBITDA expected to range between $285 million and $300 million, reflecting strong confidence in future market demand and plans for sustained investment to drive growth.
- Strong Order Growth: In 2025, Mirion booked over $1 billion in orders, including approximately $150 million from a large opportunity pipeline, demonstrating the company's diversified development in the nuclear power sector and its potential for future growth.
See More
Mirion Executives to Present at Citi's Global Industrial Tech Conference
- Executive Presentation: Mirion's Chairman and CEO Thomas Logan, along with CFO Brian Schopfer, will present at Citi's Global Industrial Tech and Mobility Conference on February 18, 2026, at 2:40 PM ET, highlighting the company's leadership in radiation safety.
- Live Webcast Details: The presentation will be webcast live on Mirion's Investor Relations Page, where a link will be available under the 'Events and Presentations' section, ensuring investors can access real-time updates on the company's developments.
- Company Overview: Mirion is a global leader in radiation safety, science, and medicine, dedicated to delivering vital protection through innovative technologies that serve R&D labs, nuclear facilities, and healthcare, showcasing its broad application potential across diverse markets.
- Global Operations: Headquartered in Atlanta, GA, Mirion employs approximately 3,200 people and operates in 12 countries, demonstrating its significant influence and market penetration in the global radiation safety technology sector.
See More
Mirion Technologies Reports Record Orders and Strong 2026 Guidance
- Record Orders: Mirion Technologies achieved over $1 billion in orders for 2025, primarily driven by strong performance in the nuclear power market, with expectations for continued double-digit organic growth into 2026, highlighting the company's strategic advantage in the nuclear sector.
- Acquisition-Driven Growth: The acquisitions of Certrec and Paragon Energy Solutions have increased Mirion's nuclear power revenue to approximately 40% of total revenue, which not only strengthens the company's market position but also lays a solid foundation for future growth.
- 2026 Financial Outlook: The company expects total revenue growth of 22% to 24% for 2026, with adjusted EBITDA projected between $285 million and $300 million, indicating robust profitability and sustained market demand.
- Adjusted Free Cash Flow: Adjusted free cash flow for 2026 is expected to range from $155 million to $175 million, reflecting ongoing improvements in capital management and operational efficiency, further enhancing investor confidence.
See More
Mirion (MIR) Q4 2025 Earnings Call Transcript
See More
Mirion Appoints New Executives to Drive Growth Strategy
- Nuclear Strategy Leadership: Tighe Smith has been appointed as Chief Nuclear Officer to lead the global nuclear strategy, leveraging over 20 years of nuclear engineering experience to ensure Mirion remains competitive in the rapidly expanding advanced small modular reactor market, thereby driving long-term growth in the nuclear sector.
- Nuclear Medicine Market Expansion: Shelia Webb has been promoted to President of Nuclear Medicine, focusing on integrating the ec2Software and Capintec brands to advance cancer care, utilizing her successful experience in building digital ecosystems to enhance Mirion's position in this evolving market.
- AI Strategy Innovation: Shahmeer Mirza has been appointed as Chief Artificial Intelligence & Digital Officer, tasked with driving Mirion's digital transformation by implementing responsible AI strategies to optimize operational processes and create new revenue streams, thus improving overall operational efficiency.
- Enhanced Global Impact: Mirion's solutions are deployed in over 98% of the world's nuclear power plants and more than 6,000 cancer centers, and these executive appointments further strengthen the company's ability to deliver safe and reliable innovations in highly regulated environments, ensuring meaningful value for global users.
See More
Mirion Technologies Q4 Earnings Analysis
- Earnings Performance: Mirion Technologies reported a Q4 non-GAAP EPS of $0.15, missing expectations by $0.01, indicating pressure on profitability that could undermine investor confidence.
- Revenue Growth: The company achieved revenue of $277.4 million, reflecting a 9.1% year-over-year increase; however, it fell short of expectations by $3.77 million, suggesting that market demand has not fully translated into sales growth, which may impact future business expansion.
- Market Reaction Analysis: Given the disappointing earnings report, Mirion Technologies' stock price may face downward pressure, prompting investors to closely monitor the company's strategic adjustments and market performance to assess its long-term investment value.
- Future Outlook: Despite current challenges reflected in the earnings report, the company must leverage innovation and market expansion to enhance performance in a competitive landscape, ensuring sustainable growth moving forward.
See More
Mirion Reports 9.1% Revenue Growth in Q4
- Significant Revenue Growth: Mirion reported fourth-quarter revenues of $277.4 million for 2025, reflecting a 9.1% year-over-year increase, indicating strong demand in the nuclear and medical markets that further solidifies its market position.
- Net Income Improvement: The GAAP net income for Q4 was $17.8 million, an 11.9% increase from $15.9 million in the same quarter of 2024, showcasing the company's success in cost control and operational efficiency, which enhances investor confidence.
- Optimistic Guidance: Mirion anticipates a total revenue growth rate of 22% to 24% for 2026, with adjusted EBITDA expected to range between $285 million and $300 million, reflecting strong confidence in future market demand and plans for sustained investment to drive growth.
- Strong Order Growth: In 2025, Mirion booked over $1 billion in orders, including approximately $150 million from a large opportunity pipeline, demonstrating the company's diversified development in the nuclear power sector and its potential for future growth.
See More
